Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With a pioneering gene therapy now on the brink of approval, this feature highlights some of the key deals and news in the field in the past five years.
Despite recent clinical trial failures, there is a robust dealmaking and funding environment for companies tackling diseases of the central nervous system, indicating that eventual success is expected.
What are the key steps in preparing nonconfidential material to present to potential partners? In this article, experts at inVentiv Health Consulting discuss how to make the best case for your organization in the current dealmaking climate.
Checkpoint inhibitors continue to achieve clinical and commercial success, which has led to further deals and combination trials as developers look to maximize their reach. In this feature, we update our chart of the development progress and major deals for the leading checkpoint inhibitors.
While breast cancer and ovarian cancer continue to be a major focus of R&D investment and dealmaking, other indications related to women’s health, such as hot flushes and endometriosis, are also attracting interest.
Following on from the success of monoclonal antibodies in oncology, analysts predict big sales from antibody–drug conjugates, while advances in the underlying platforms continue to drive dealmaking.
Data on sales, financing and major deals for vaccines for infectious diseases provide an outlook into the development of the commercial landscape for such products.
Diagnostics for applications in oncology—particularly immuno-oncology—continued to be the most common focus of dealmaking in the past 12 months, while deals related to Alzheimer’s disease and infectious disease threats such as Zika virus infection were also prominent.
Although the volume and value of merger and acquisition (M&A) deals in the medtech industry both increased in 2016 compared with 2015, M&A activity declined during the year, reflecting the challenges that the industry faces.
Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade.
Exploration by biopharma companies of new biological pathways underlying skin disorders is leading to the entry of potential blockbusters into the dermatology market, and fueling high-value deals.
Partnering activity in the microbiome space exploded in 2016, and with the first inroads into clinical development well under way, 2017 is shaping up as a pivotal year for the microbiome’s therapeutic and market potential to blossom.
Universities have long been viewed as important to the economic and social well-being of their communities, but in recent years expectations have changed.
